Addiction Expert Dr. Indra Cidambi Highlights Hurdles to Overcome for Wide Adoption
New York – December 1, 2017 – The Food & Drug Administration (FDA) announced yesterday its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady dose of buprenorphine for one month. Buprenorphine works by reducing cravings and withdrawal symptoms and Sublocade is recommended for patients stabilized on a steady, maintenance dose of buprenorphine for seven days.
“Sublocade offers ...Continue Reading →